Rush Medical Center Home Page Information for healthcare Professionals Rush University
FIND A DOCTOR
PATIENT & VISTOR SERVICES
HEALTH INFORMATION
CLINICAL SERVICES
EVENTS & CLASSES
RUSH NEWS ROOM
CLINICAL TRIALS
RESEARCH AT RUSH
NURSING AT RUSH
WORK AT RUSH
GIVING TO RUSH

Bookmark This Page
Clinical Trails at Rush Hepatitis C Study Using Antiviral Treatment
Clinical Trial Protocol ID
08062002

Clinical Trial Investigator Name
David Van Thiel

Clinical Trial Title

Study of a thrombopoietin receptor agonist, for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin.



Clinical Trial Protocol Description

This study will evaluate sustained virological response rates as well as evaluate the safety and tolerability of the study drug as compared with placebo.



Clinical Trial Eligibility Criteria

You may be eligible to participate in this study if you:

  • Have evidence of HCV infection
  • Are a candidate for peginterferon alfa-2b and ribavirin combination anti-viral therapy

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.





Contact Name Doris Yadav
Contact Phone (312) 563-3919
Contact E-mail clinical_trials@rush.edu
Promotional Information

Clinical Trials Home
Infectious Disease Trials
Hepatitis C Study Using Antiviral Treatment

   
Find a Doctor | Patient & Visitor Services | Health Information
Clinical Services | Events & Classes | Rush News Room | Clinical Trials
Research At Rush
Disclaimer | Privacy Statement | Site Map

© Rush University Medical Center, Chicago, Illinois